A&O Shearman supports GSK on its AI license and partnership with Noetik

Noetik will license its OCTO-VC virtual cell AI models to GSK for a minimum of five years and collaborate with GSK to create human spatial datasets relating to non-small cell lung cancer and colorectal cancer. It is an innovative commercial arrangement that supports GSK’s strategy of combining its own leading AI capabilities with select third party partnerships.

Alex Shandro commented: “Working with GSK and Noetik on such an innovative arrangement underscores the strategic value of AI-enabled drug discovery and the evolving roles of AI-native biotech and pharma companies within the AI value chain. Combining cutting-edge AI technologies with GSK’s established AI capabilities has the potential to accelerate insights in some of the most complex disease areas. We are proud to support a collaboration that not only advances our client’s innovation agenda but also helps redefine the commercial frameworks that will shape the future of AI in biotech.”

The A&O Shearman team was led by AI transactions partner Alex Shandro, supported by senior associate Megan McMellon and associate Millie Fantham.